Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Agios Pharma (AGIO) PT Raised to $55 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $55.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "AGIO reported its 2Q24 update concurrent with the ACTIVATE-KidsT (pediatric PKD) topline results which missed the prespecified... More
